ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition to the controversially discussed accessibility of stem cells to medication [7, 15, 21, 25, 28], key properties will include modelling of signalling systems more broadly to include effects of drug on individual components of the signalling pathways in CML, including e.g. off-target (i.e. non-ABL) effects of drug.